Several possible studies
Story checked
Stem Cell Therapy for Ankylosing Spondylitis (opens in a new tab)
webmd.com · 2024-09-22
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Stem Cell Therapy for Ankylosing Spondylitis
webmd.com · 2024-09-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedStem cell therapy is not yet approved to treat ankylosing spondylitis, and unproven clinic claims should be treated with caution.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedScientists are studying mesenchymal stem cell therapies for ankylosing spondylitis, including the idea that healthy donor stem cells might help correct an immune imbalance and ongoing inflammation.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedThe article says the evidence so far is very limited: the studies have been very small or done in animals, but the early research appears promising.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedOne study reportedly found that umbilical cord mesenchymal stem cell therapy eased AS symptoms in all five participants, including less pain during certain exercises and in general.View evidenceHide evidence
As statedall five people
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedAnother study reportedly gave bone marrow-derived mesenchymal stem cells to 31 people with active AS, and 7 out of 10 people improved after four infusions, with effects lasting up to 7 weeks, though nobody’s AS completely resolved.View evidenceHide evidence
As stated31 people; 7 out of 10 people; up to 7 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedMouse studies suggest mesenchymal stem cells can alter inflammatory cells, and the article says stem cell therapy may help repair tissue damage seen in AS.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedThe article says clinical trials have found mesenchymal stem cell therapy for AS to be safe and not to cause severe side effects, with common side effects including a short fever after infusion and pain at the needle site.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedThe article gives examples of coincident remission after autologous hematopoietic stem cell transplant for other diseases, including a 75-year-old woman with AS after transplant for multiple myeloma and a man whose AS-related spine and hip pain improved after transplant for lymphoma.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Sequential Clinical Changes Following Autologous Mesenchymal Stem Cell Therapy in a Patient With Concurrent Huntington's Disease and Ankylosing Spondylitis: A Case Report.
Cureus · 2026 · PubMed, Europe PMC
Review for "IL‐ 17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation towards Bone‐forming cells in ankylosing spondylitis"
2020 · Crossref
Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy.
2026 · Europe PMC
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.
2026 · Europe PMC
Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global score (BASG)
Clinical Rheumatology · 2008 · Crossref
And 10 more candidates considered.